Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 594 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... June 14, 2021 Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival December 7, 2018 New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... February 14, 2020 Load more HOT NEWS En gran cantidad de casos el exito o examen experto os... Your NCI: Top Priorities from AACR 2026 Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? Quitting Smoking Improves Survival in People with Lung Cancer
